Physician profile
May S Chen
NPI 1881772887
$5,450.88
in general payments reported to CMS, 2019-2025
26 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $423 · 2021: $536 · 2022: $922 · 2023: $905 · 2024: $999 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $759.41 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $679.95 | 2021-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $633.92 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $498.68 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $491.27 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Amgen INC. | $471.45 | 2019-2024 | Parsabiv, Aranesp, Tavneos |
| Akebia Therapeutics INC | $349.90 | 2019-2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $197.90 | 2023-2025 | |
| Glaxosmithkline, LLC. | $171.51 | 2021-2023 | Benlysta |
| Ardelyx, INC. | $165.65 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $155.65 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.88 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $121.82 | 2025 | |
| Janssen Pharmaceuticals, INC | $106.02 | 2019 | |
| Calliditas Therapeutics US INC. | $77.75 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $76.68 | 2024-2025 | Ultomiris |
| Novo Nordisk INC | $65.53 | 2024-2025 | Ozempic |
| Travere Therapeutics, INC. | $65.11 | 2025 | |
| Kyowa Kirin, INC. | $56.74 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $50.48 | 2019 | |
| Opko Pharmaceuticals, LLC | $35.70 | 2019-2024 | Rayaldee |
| Lilly USA, LLC | $27.61 | 2025 | Jardiance |
| Boston Scientific Corporation | $19.59 | 2021 | |
| Horizon Therapeutics Plc | $18.85 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.07 | 2024 | Arcalyst |
| Aurinia Pharma U.S., INC. | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.